A March 2 lawsuit filed in California state court alleges dietary supplements with omega-3 fatty acids have "undisclosed and unnecessarily high levels of contamination with polychlorinated biphenyl compounds." Environmental advocates and the Mateel Environmental Justice Foundation name as defendants: CVS Pharmacy Inc., General Nutrition Corp., Now Health Group Inc., Omega Protein Inc., Pharmavite LLC, Rite Aid Corp., Solgar, Inc. and TwinLab Corp. The lawsuit alleges the supplements have PCB levels above the "safe harbor" limit set for human consumption under California's Proposition 65, which requires warnings about such exposures on product labels. The Council for Responsible Nutrition says the levels of PCBs found in the majority of the products do not appear to exceed the Prop 65 limit of 90 ng per day
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
HHS Secretary Kennedy's new ACIP appointments include multiple members of anti-vaccine groups and people who have spread misinformation about COVID-19 vaccines.
Commissioner Martin Makary told staff that plans are being developed to centralize HR, IT, travel and other functions, which were heavily impacted by the 1 April reduction-in-force.
The House Appropriations Committee wants an analysis of how issues that led to CRLs could have been resolved within the first review cycle and seeks an agency crackdown on counterfeit GLP-1 agonists.
